Study objective: Angiotensin-converting enzyme inhibitors (ACE-I) are considered safe, but they are associated with characteristic side effects, namely cough and angioedema, usually requiring discontinuation. We perceived that referrals for these side effects have become more and more frequent; therefore, we evaluated the degree of knowledge on the safety of ACE-I in different medical categories. 
A ngiotensin-converting enzyme inhibitors (ACE-I) are currently among the most largely prescribed drugs. There are numerous ACE-I, with variable pharmacokinetic characteristics, but they share the same mechanism of action and pharmacodynamic properties. In Italy, at least 13 different molecules are currently marketed. ACE-I are effective in reducing BP, exert a beneficial effect in congestive heart failure, 1, 2 and can decrease the mortality rate after cardiac ischemic stroke. 3 ACE-I are considered safe overall, 4 and this is one of the principal reasons for their popularity. Nevertheless, these agents are associated with characteristic side effects. These side effects are usually non-life threatening but are always disturbing for patients, and often require treatment discontinuation. The most common side effect is cough, which occurs overall in 15% up to 30% of patients, depending on case series. 5, 6 It is sustained by an accumulation of kinins provoked by the inhibition of ACE. This effect can also lead to bronchospasm, but overt asthma appears only in a minority of patients. 6, 7 Another characteristic side effect is angioedema that occurs in 0.1 to 0.2% of patients 8 and can appear even after many years of use of the drug. Angioedema preferentially involves the face and mouth, but abdominal organs may also be involved. 8, 9 In the case of angioedema, the underlying pathogenic mechanism is less clear.
It is true that the occurrence of side effects may differ from molecule to molecule, but they are clearly class related. Recently, a new class of drugs acting on the angiotensin network has been introduced in clinical practice, the so-called sartans. They block the angiotensin II receptor and are therefore considered more selective than ACE-I, but cough and angioedema are still present with that new class of drugs. 10 Usually, patients with chronic cough or angioedema are referred to allergy/pulmonology units for diagnosis. In the recent years, we perceived that the referrals of patients with side effects due to ACE-I have become more and more frequent. Based on this observation, we attempted to evaluate the degree of knowledge about the safety profile of ACE-I in physician categories usually prescribing these drugs (cardiologists and general practitioners [GPs] ). Allergists were also examined, since they are expected to diagnose and treat the side effects. We developed a questionnaire specifically dealing with ACE-I side effects and distributed it to a random sample of physicians.
Methods and Methods
A simple questionnaire based on the more recent and updated literature in the field was prepared. It consisted of 13 multiplechoice questions about the epidemiology, clinical features, and management of ACE-I side effects. A summary of the questionnaire is reported in Table 1 . In the case of multiple correct answers (questions 3, 9, 10), all of them had to be marked to consider the answer response as correct. The questionnaire also contained some basic demographic information, such as age, sex, years of practice, and position. Physicians were randomly selected from the public general registry of specialists and GPs in Brescia and Verona (northwest and northeast Italy, respectively). Questionnaires were posted with envelopes for returning provided, and they were kept anonymous. Only those questionnaires completely filled out (all demographic data and all questions answered) were analyzed. The data from the returned questionnaires were evaluated by using statistical software (SAS Version 9.1, SAS Institute; Cary, NC).
Results
Three hundred twelve physicians were contacted, 164 questionnaires (55%) were returned, and 154 questionnaires (49% of the total) were eligible for analysis. Of the 154 physicians, 75 physicians (48%) were male. The mean age was 45 years (age range, 28 to 57 years). The mean time elapsed from medical doctor degree was 17.5 years (range, 4 to 22 years). The physicians were distributed as follows: 48 cardiologists, 52 GPs, and 54 allergists. No difference among the three groups ( 2 test) was detectable concerning demography.
The percentage of correct answers was quite low (Table 2) : on average, 31.9% for cardiologists, 40% for GPs, and 33% for allergists. Thus, GPs provided a significantly higher percentage of correct answers compared to cardiologists and allergists (p ϭ 0.05). No significant difference in the percentage of correct answers could be detected among the different age classes (25 to 34 years, 35 to 44 years, 45 to 54 years, and 55 to 65 years). The lower rate of correct answers (0 to 15.9%) in all medical categories was about the time of onset of cough and the action to take for managing it (questions 2, 3). On the contrary, a high rate was achieved (73.5 to 100%) concerning the disappearance of cough after discontinuation and the race-related risk factor (questions 4, 5). Few physicians were able to identify the correct time for disappearance of angioedema after drug discontinuation (question 11; 0 to 15.4%). Cardiologists seemed to be less aware of the fact that sartans can cross-react with ACE-I as far as angioedema and cough are concerned (question 13).
Discussion ACE-I are largely used in everyday clinical practice. Despite their well-known efficacy in several diseases (arterial hypertension, ischemic stroke, congestive heart failure), their side effects can represent a troublesome problem for patients. In general, cardiologists and GPs are the physicians who more frequently prescribe ACE-I, whereas allergists are often involved in diagnosing and managing the most common side effects (chronic cough and angioedema). Our general impression is that in the last few years, the number of outpatients referred with chronic cough or angioedema, in whom ACE-I side effects were subsequently diagnosed, has been increasing. For instance, at our center the percentage of such patients has increased Ͼ 20% compared to the previous year. Therefore, we evaluated the degree of knowledge of the safety profile of ACE-I among physicians by a dedicated questionnaire, in a large area of northern Italy. The results of the survey are quite surprising, since the knowledge of the side effects of ACE-I resulted to be very poor. GPs provided the highest rate of correct answers to the questionnaire, as compared to cardiologists and allergists (who manage the side effects). We acknowl- edge that several questions proposed in the questionnaire are quite specialistic, but it is also true that the rate of correct responses is fairly lower (Ͻ 40%) than expected on the basis of a generic knowledge of the argument. The poor awareness of the side effects due to ACE-I, by GPs and cardiologists, can partly explain the observed increase in referrals for chronic cough and angioedema. We conclude that a more strict and bidirectional synergy is needed between specialists and GPs to improve knowledge on the safety of ACE-I. Also, we speculate that a better knowledge of the argument would result in an economic savings related to the reduced number of referrals for specialty consultations. 
